Arrowhead Pharmaceuticals

YTD

ALL

Trade Arrowhead Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ARWR

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC.

CEO

Christopher Richard Anzalone

CEOChristopher Richard Anzalone

Employees

711

Employees711

Headquarters

Pasadena, California

HeadquartersPasadena, California

Founded

1989

Founded1989

Employees

711

Employees711

ARWR Key Statistics

Market cap

10.98B

Market cap10.98B

Price-Earnings ratio

-36.26

Price-Earnings ratio-36.26

Dividend yield

—

Dividend yield—

Average volume

1.53M

Average volume1.53M

High today

$78.78

High today$78.78

Low today

$73.50

Low today$73.50

Open price

$78.39

Open price$78.39

Volume

1.44M

Volume1.44M

52 Week high

$82.26

52 Week high$82.26

52 Week low

$14.30

52 Week low$14.30

Stock Snapshot

As of today, Arrowhead Pharmaceuticals(ARWR) shares are valued at $73.50. The company's market cap stands at 10.98B, with a P/E ratio of -36.26.

On 2026-05-31, Arrowhead Pharmaceuticals(ARWR) stock traded between a low of $73.50 and a high of $78.78. Shares are currently priced at $73.50, which is 0.0% above the low and -6.7% below the high.

The Arrowhead Pharmaceuticals(ARWR)'s current trading volume is 1.44M, compared to an average daily volume of 1.53M.

During the past year, Arrowhead Pharmaceuticals(ARWR) stock moved between $14.30 at its lowest and $82.26 at its peak.

ARWR News

Simply Wall St 3d

Assessing Arrowhead Pharmaceuticals Valuation After New Plozasiran And ARO INHBE Clinical Results - simplywall.st

...

TipRanks 3d

Arrowhead’s Inhaled ARO-RAGE Asthma Trial Enters Active Recruitment, Keeping a Key Pipeline Catalyst in Play

Arrowhead Pharmaceuticals, Inc. (ARWR) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium,...

TipRanks 4d

Arrowhead Pharmaceuticals: Buy Rating Reaffirmed as ARO-INHBE Data Strengthen Outlook and $100 Price Target Maintained

Analyst Michael Ulz of Morgan Stanley maintained a Buy rating on Arrowhead Pharmaceuticals, retaining the price target of $100.00. Unlock trusted, data-backed...

Analyst ratings

85%

of 13 ratings

Buy

84.6%

Hold

15.4%

Sell

More ARWR News

TipRanks 5d

Arrowhead presents clinical cardiometabolic data at EAS Congress

Arrowhead (ARWR) Pharmaceuticals presented new clinical data for plozasiran supporting its use in patients with moderate-to-severe renal impairment or moderate...

People also own

Based on the portfolios of people who own ARWR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.